Multidrug nanoformulations of vitamin D, anandamide and melatonin as a synergistic treatment for vascular inflammation

VIRNA MARTÍN GIMENÉZ; RUSSEL J. REITER; WALTER MANUCHA

DRUG DISCOVERY TODAY

ELSEVIER SCI LTD

Año: 2023 vol. 28 p. 1 - 3

1359-6446

The pharmaceutical nanoformulations would require a smart and complex design, since vitamin D and anandamide are lipophilic compounds, while melatonin is an amphiphilic drug. Therefore, it is to be expected that these three drugs are not able to interact with the carrier in the same way. Moreover, it is assumed that, to avoid disruptions in circadian and biological rhythms, vitamin D should be released during the day, whereas melatonin should be do it at night, and anandamide should probably be released both during the day and at night. These examples are just a few of the many aspects that must be considered at the moment of designing this new multidrug therapeutic formulation. For that reason, the principles of conventional pharmaceutical technology cannot be used to achieve the type of development proposed here, but rather the multiple benefits offered by nanotechnology and nanomedicine need to be explored in order to do so. In this sense, the versatility and wide variety of nanocarriers developed to date allows either the physical encapsulation or chemical conjugation of different drugs with multiple nanomaterials or nanocarrier portions depending on the physical and chemical features of the drugs of interest, making possible the co-formulation of two or more therapeutic compounds simultaneously. In addition, the possibility of developing nanocarriers that respond to different stimuli, such as pH, light, temperature, enzymatic cleavage, among others, would allow a controlled drug release either jointly or separately to avoid an imbalance of homeostasis in patients. Thus, the design and development of a smart multidrug nanoformulation composed of vitamin D, anandamide and melatonin could be proposed as a novel synergistic treatment of natural origin for vascular inflammation and its related cardiovascular diseases.